ZTS

Zoetis Inc.
CAPPED RATING

Zoetis Inc is a developer and manufacturer of drugs providing medicines for animal health, and vaccines for livestock and companion animals. Its products are anti-infectives, vaccines, parasiticides, medicated feed additives and other related products.

Zoetis Inc. (ZTS) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (F). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B
Factor Score 3.2 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
B+
Factor Score 3.7 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
F
Factor Score 0.3 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 14.1
EV / EBITDA N/A
Rev Growth YoY -1.3%
Gross Margin 71.6%
Price Return 3M 15.7%
Price Return 12M -29.3%
Catalyst Signal +0.03
Market Cap $34.1B
TTM Revenue $9.5B
Price / Sales 3.6
ROE 57.6%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B (3.2) D+ (1.8) B+ (3.7) B- (3.1) F (0.3) C (2.4)
2026-11-09 B (3.2) D+ (1.8) B+ (3.7) C+ (2.7) F (0.3) C (2.4)
2026-11-07 B (3.2) D+ (1.8) B+ (3.7) C (2.2) F (0.3) C (2.2)
2026-11-05 B (3.2) C- (1.9) B+ (3.7) C (2.2) F (0.4) C (2.3)
2026-11-04 B (3.2) D+ (1.8) B+ (3.7) C- (2.1) F (0.1) C (2.2)
Page 1 of 11
…